m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00378)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
RARA
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | FTO enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through regulating expression of targets such as ASB2 and Retinoic acid receptor alpha (RARA) by reducing m6A levels in these mRNA transcripts. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Acute myeloid leukaemia | ICD-11: 2A60 | ||
Responsed Drug | Tretinoin | Approved | ||
Cell Process | RNA stability | |||
RNA degradation (hsa03018) | ||||
In-vitro Model | K-562 | Chronic myelogenous leukemia | Homo sapiens | CVCL_0004 |
KOCL-48 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_6867 | |
Mono-Mac-6 | Adult acute monocytic leukemia | Homo sapiens | CVCL_1426 | |
Acute myeloid leukaemia [ICD-11: 2A60]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | FTO enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through regulating expression of targets such as ASB2 and Retinoic acid receptor alpha (RARA) by reducing m6A levels in these mRNA transcripts. | |||
Responsed Disease | Acute myeloid leukaemia [ICD-11: 2A60] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Responsed Drug | Tretinoin | Approved | ||
Cell Process | RNA stability | |||
RNA degradation (hsa03018) | ||||
In-vitro Model | K-562 | Chronic myelogenous leukemia | Homo sapiens | CVCL_0004 |
KOCL-48 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_6867 | |
Mono-Mac-6 | Adult acute monocytic leukemia | Homo sapiens | CVCL_1426 | |
Tretinoin
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | FTO enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through regulating expression of targets such as ASB2 and Retinoic acid receptor alpha (RARA) by reducing m6A levels in these mRNA transcripts. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Acute myeloid leukaemia | ICD-11: 2A60 | ||
Cell Process | RNA stability | |||
RNA degradation (hsa03018) | ||||
In-vitro Model | K-562 | Chronic myelogenous leukemia | Homo sapiens | CVCL_0004 |
KOCL-48 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_6867 | |
Mono-Mac-6 | Adult acute monocytic leukemia | Homo sapiens | CVCL_1426 | |